8-K: Edgewise Therapeutics Announces Positive Topline Results from Phase 2 CANYON Trial for Becker Muscular Dystrophy

Edgewise Therapeutics' Phase 2 CANYON trial of sevasemten in Becker muscular dystrophy met its primary endpoint, showing a significant reduction in creatine kinase levels.

Summary

• Edgewise Therapeutics announced positive topline results from the Phase 2 CANYON trial of sevasemten in individuals with Becker muscular dystrophy.
• The CANYON trial is the largest interventional Becker muscular dystrophy trial to date, enrolling 40 adults and 29 adolescents.
• The primary endpoint, change from baseline in creatine kinase (CK) levels, was met with a 28% average decrease in the sevasemten-treated group compared to placebo over months 6 through 12 (p=0.02).
• The key secondary endpoint, change from baseline in North Star Ambulatory Assessment (NSAA) score at month 12, showed a 1.1 point difference favoring sevasemten (p=0.16).
• Plasma fast skeletal muscle troponin I (TNNI2) decreased 77% from baseline in the sevasemten-treated group compared to placebo (p<0.001).
• Other secondary endpoints, including the 10-meter walk/run, 4-stair climb, and 100-meter timed test, showed trends towards improvement compared to placebo.
• Sevasemten was well-tolerated, and no new safety concerns were identified.
• The company is on track to complete recruitment for the GRAND CANYON pivotal cohort by the first quarter of 2025.
• The company plans to engage with the FDA and European Medicines Agency regarding marketing authorization filing strategies for sevasemten in Becker.

Sentiment

Score: 8

Explanation: The document presents positive topline results from a Phase 2 trial, meeting the primary endpoint and showing promising trends in secondary endpoints. The company is also well-capitalized and has a clear path forward with the GRAND CANYON trial. However, there are some risks and uncertainties associated with clinical trials and regulatory approvals.

Positives

• The trial met its primary endpoint with a statistically significant reduction in CK levels.
• There was a significant reduction in TNNI2 levels, indicating reduced muscle damage.
• NSAA scores remained stable in the sevasemten group, suggesting a potential for functional stabilization.
• Sevasemten was well-tolerated with no new safety concerns.
• The results support the progression to the GRAND CANYON pivotal trial.
• The company is on track to complete recruitment for the GRAND CANYON cohort by Q1 2025.
• The company plans to engage with regulatory agencies regarding marketing authorization.

Negatives

• There was a notable imbalance in baseline disease severity between the sevasemten and placebo groups, with the sevasemten group having more advanced disease.
• The key secondary endpoint, NSAA, did not reach statistical significance (p=0.16).
• The trial was not powered for functional endpoints.

Risks

• The imbalance in baseline disease severity between treatment groups could affect the interpretation of some results.
• The NSAA endpoint did not reach statistical significance in the CANYON trial, although trends favored sevasemten.
• The success of the GRAND CANYON trial is not guaranteed, and results may differ from the CANYON trial.
• The company's ability to obtain regulatory approvals and commercialize sevasemten is subject to various risks and uncertainties.
• The company may need to raise additional funding to continue its business and product development plans.

Future Outlook

The company plans to engage with the FDA and European Medicines Agency regarding marketing authorization filing strategies for sevasemten in Becker, and is on track to complete recruitment for the GRAND CANYON pivotal cohort by the first quarter of 2025. The company also intends to submit the complete results of the CANYON study for publication at a future medical congress.

Management Comments

• Craig M. McDonald, M.D., stated that the study presents compelling biomarker data and promising signals that suggest the potential for functional stabilization with sevasemten.
• Joanne Donovan, Ph.D., M.D., Chief Medical Officer, said they are very encouraged by the CANYON results and the potential of this novel muscle-targeted therapeutic.
• Joanne Donovan also stated that the results confirmed previous observations in the ARCH study of significant decreases in biomarkers of muscle damage and evidence of preservation of function in Becker patients.

Industry Context

This announcement is significant as there are currently no approved therapies for Becker muscular dystrophy, and the positive results from the CANYON trial suggest that sevasemten could potentially be the first treatment option for this patient population. The company is also advancing other programs for muscular dystrophies and cardiac conditions, indicating a broad focus on muscle-related diseases.

Comparison to Industry Standards

• The CANYON trial is the largest interventional trial to date in Becker muscular dystrophy, making it a significant study in the field.
• The observed 28% reduction in CK levels is a notable result compared to natural history data, where CK levels typically increase over time.
• The stabilization of NSAA scores in the sevasemten group is a positive signal, as natural history studies show a consistent decline in NSAA over time.
• The 77% reduction in TNNI2 levels is a strong indicator of reduced muscle damage, which is a key target for therapies in muscular dystrophies.
• The company's approach of using a fast skeletal myosin inhibitor is a novel mechanism of action compared to other therapies in development for muscular dystrophies.
• The company is using the North Star Ambulatory Assessment (NSAA) as a key functional endpoint, which is a widely accepted and validated measure in the field of muscular dystrophy research. Comparible companies such as Sarepta Therapeutics and PTC Therapeutics also use NSAA as a key endpoint in their clinical trials for Duchenne Muscular Dystrophy.

Stakeholder Impact

• Shareholders: The positive results are likely to be viewed favorably by investors, potentially increasing the company's stock value.
• Patients: The results offer hope for a potential treatment for Becker muscular dystrophy, a disease with no approved therapies.
• Employees: The positive results may boost morale and confidence in the company's mission and development programs.
• Researchers: The data provides valuable insights into the potential of sevasemten and the progression of Becker muscular dystrophy.

Next Steps

• The company will complete recruitment for the GRAND CANYON pivotal cohort by the first quarter of 2025.
• The company plans to engage with the FDA and European Medicines Agency regarding marketing authorization filing strategies for sevasemten in Becker.
• The company intends to submit the complete results of the CANYON study for publication at a future medical congress.
• The company will continue to evaluate additional secondary and exploratory endpoints from the CANYON trial.

Key Dates

Keywords

Becker muscular dystrophy, sevasemten, EDG-5506, CANYON trial, GRAND CANYON trial, muscle disease, clinical trial, biomarkers, NSAA, creatine kinase, TNNI2, muscle damage, FDA, EMA, Orphan Drug Designation